OpportunityAnalyzer: Uveitis Opportunity Analysis and Forecasts to 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Uveitis is an inflammatory condition of the eye affecting mainly the uvea. It encompasses a heterogeneous collection of disorders characterized by ocular inflammation. Currently, there is only a limited number of approved drugs for the treatment of uveitis. Based on the diverse nature of uveitis , there is a high unmet need for varied therapy approaches. Significant efforts are being made to develop new treatments for uveitis, as current pharmacologic management, which is dominated by competitively priced corticosteroids and also immunosuppressive drugs, is notorious for the development of adverse side effects.
 
GlobalData estimates the drug sales for uveitis in 2016 were approximately $416.5M across the 7MM covered in this report. Over the 10-year forecast period, the market is expected to grow to $897.1M at a CAGR of 8.0%.

The anticipated introduction of five new drugs will further drive the market by offering novel treatment mechanisms, including new drug delivery routes and novel, non-corticosteroid drug molecules. These new drugs will expand the options available to treat uveitis patients and contribute to overall market growth.

Scope

Overview of uveitis: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized uveitis market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including non-infectious mild and moderate anterior uveitis, non-infectious severe anterior uveitis, non-infectious intermediate, posterior and panuveitis), forecast from 2016 to 2026.

Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the uveitis therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for uveitis therapy. The most promising candidate in Phase III (and Phase II/III) development is profiled.

Analysis of the current and future market competition in the global uveitis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global uveitis therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global uveitis therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AbbVie
Aciont
Alcon
Aldeyra
Alimera Sciences
Allergan
AlphaMab
Amgen
Bauch & Lomb
Biocad
BIOCND
Biocon
Biogen
Boehringer Ingelheim
Bristol-Myers Squibb
Clearside Biomedical
Coherus BioSciences
CyDex Pharmaceuticals
Daiichi Sankyo
Eisai
Enzo Biochem
Eyegate Pharmaceuticals
Eyevensys SAS
Fresenius SE & Co KGaA
Fujifilm Kyowa Kirin Biologics
Galapagos NV
Genor BioPharma
Gilead
Hetero Drugs
Innovent Biologics
LG Chem
Meiji Seika Pharma
Merck
Mitotech SA
Mochida Pharamceutical
Momenta Pharmaceuticals
MorphoSys
NovaMedica
Novartis
Oculis ehf
Oncobiologics
OphthaliX
Ophthotech
Panoptes Pharma GesmbH
Pfizer
pSivida
Samsung Bioepis
Sandoz
Santen
Sanwa Kagaku Kenkyusho
Valeant Pharmaceuticals

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Significant Growth Is Expected in the Uveitis Market from 2016 to 2026

2.2 R&D and Corporate Strategies Within the Uveitis Market

2.3 A Long-Acting Treatment That Permanently Controls Inflammation, With a Good Short- and Long-Term Safety Profile, Remains Elusive

2.4 Market Opportunities for New Entrants

2.5 Late-Stage Pipeline Drugs Entering the Uveitis Market Will Be a Key Driver of Growth

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

4.2.1 Uveitis and Systemic Diseases

4.3 Symptoms

4.4 Prognosis

4.5 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.3.1 US

5.3.2 5EU

5.3.3 Japan

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Uveitis (2016–2026)

5.5.1 Diagnosed Incident Cases of Uveitis

5.5.2 Diagnosed Prevalent Cases of Uveitis

5.5.3 Age-Specific Diagnosed Prevalent Cases of Uveitis

5.5.4 Sex-Specific Diagnosed Prevalent Cases of Uveitis

5.5.5 Diagnosed Prevalent Cases by Anatomical Site of Inflammation

5.5.6 Diagnosed Prevalent Cases by Etiology

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Current Treatment Options

6.1 Overview

6.2 Diagnosis and Treatment

6.2.1 Diagnosis

6.2.2 Treatment Guidelines and Leading Prescribed Drugs

6.3 Clinical Practice

6.4 Humira (Adalimumab)

6.4.1 Overview

6.4.2 Efficacy

6.4.3 Safety

6.4.4 SWOT Analysis

6.5 Retisert (Flucinolone Acetonide)

6.5.1 Overview

6.5.2 Efficacy

6.5.3 Safety

6.5.4 SWOT Analysis

6.6 Ozurdex (Dexamethasone Acetate)

6.6.1 Overview

6.6.2 Efficacy

6.6.3 Safety

6.6.4 SWOT Analysis

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Therapies That Maintain Vision and Control Inflammation

7.2.1 Unmet Need

7.2.2 Gap Analysis

7.2.3 Opportunity

7.3 Therapies With Improved Safety Profiles

7.3.1 Unmet Need

7.3.2 Gap Analysis

7.3.3 Opportunity

7.4 Long-Acting and More Efficient Treatment

7.4.1 Unmet Need

7.4.2 Gap Analysis

7.4.3 Opportunity

7.5 Increased Physician Education and Improved Treatment Guidelines

7.5.1 Unmet Need

7.5.2 Gap Analysis

7.5.3 Opportunity

7.6 Development of Biomarkers and Different Diagnostic Tests for Various Uveitic Types

7.6.1 Unmet Need

7.6.2 Gap Analysis

7.6.3 Opportunity

8 R&D Strategies

8.1 Overview

8.1.1 Uveitis as an Add-On Indication

8.1.2 Uveitis as a First Indication for a New Drug

8.1.3 Development of Ophthalmic Routes of Administration

8.1.4 Development of Novel Non-steroid Therapies

8.2 Clinical Trials Design

8.2.1 Lack of High-Quality Outcome Measures

8.2.2 Lack of Consensus on Outcome Measures

8.2.3 Corticosteroid-Sparing Therapy

9 Pipeline Assessment

9.1 Overview

9.2 Opsiria/DE-109 (Sirolimus)

9.2.1 Overview

9.2.2 Efficacy

9.2.3 Safety

9.2.4 SWOT Analysis

9.3 Durasert (Fluocinolone Acetonide)

9.3.1 Overview

9.3.2 Efficacy

9.3.3 Safety

9.3.4 SWOT Analysis

9.4 EGP-437 (Iontophoretic Dexamethasone Phospaste)

9.4.1 Overview

9.4.2 Efficacy

9.4.3 Safety

9.4.4 SWOT Analysis

9.5 CLS-TA (Triamcinolone Acetonide)

9.5.1 Overview

9.5.2 Efficacy

9.5.3 Safety

9.5.4 SWOT Analysis

9.6 ADX-102

9.6.1 Overview

9.6.2 Efficacy

9.6.3 Safety

9.6.4 SWOT Analysis

9.7 Biosimilars Assessment

9.8 Amjevita (Adalimumab Biosimilar)

9.8.1 Overview

9.8.2 SWOT Analysis

9.9 Imraldi (Adalimumab Biosimilar)

9.9.1 Overview

9.9.2 SWOT Analysis

9.10 Innovative Early Stage Approaches

9.10.1 Tesidolumab (LFG-316)

9.10.2 Orencia (Abatacept)

9.10.3 Dexamethasone Acetate (DexNP)

9.10.4 LME-636

9.10.5 Optiquel (B27-PD)

9.10.6 Filgotinib

9.11 Other Drugs in Development

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting Methodology

11.3.2 Diagnosed Prevalent Cases

11.3.3 Diagnosed Prevalent Cases by Anatomical Site of Inflammation

11.3.4 Diagnosed Cases and Drug-Treated Prevalence

11.3.5 Disease Severity

11.3.6 Drugs Included in Each Therapeutic Class

11.3.7 Launch and Patent Expiry Dates

11.3.8 General Pricing Assumptions

11.3.9 Individual Drug Assumptions

11.3.10 Generic Erosion

11.3.11 Pricing of Pipeline Agents

11.4 Primary Research – KOLs Interviewed for This Report

11.5 Primary Research – Prescriber Survey

11.6 About the Authors

11.6.1 Analyst

11.6.2 Therapy Area Director

11.6.3 Epidemiologist

11.6.4 Managing Epidemiologist

11.6.5 Global Director of Therapy Analysis and Epidemiology

11.6.6 Global Head and EVP of Healthcare Operations and Strategy

11.7 About GlobalData

11.8 Contact Us

11.9 Disclaimer

Table

Table 1: Uveitis: Key Metrics in the 7MM

Table 2: SUN Working Group Anatomic Classification of Uveitis

Table 3: SUN Working Group Descriptors in Uveitis

Table 4: SUN Working Group Descriptors in Uveitis

Table 5: Systemic Diseases Associated with Uveitis

Table 6: Symptoms and Ocular Comorbidities of Uveitis

Table 7: Prognosis for Uveitis Patients

Table 8: Risk Factors, Comorbidities, and Associated Diseases for Uveitis

Table 9: 7MM, Diagnosed Incident Cases of Uveitis, Both Sexes, All Ages, N, Select Years, 2016–2026

Table 10: 7MM, Diagnosed Prevalent Cases of Uveitis, Both Sexes, All Ages, N, Select Years, 2016–2026

Table 11: Treatment Guidelines for Uveitis

Table 12: Most Prescribed Drugs for Uveitis by Class in the Global Markets, 2016

Table 13: Summary of Minor Therapeutic Classes, 2016

Table 14: Product Profile – Humira

Table 15: Humira SWOT Analysis, 2017

Table 16: Product Profile – Retisert

Table 17: Retisert SWOT Analysis, 2017

Table 18: Product Profile – Ozurdex

Table 19: Ozudex SWOT Analysis, 2017

Table 20: Comparison of Therapeutic Classes in Development for Non-infectious Uveitis, 2016–2026

Table 21: Product Profile – Opsiria

Table 22: Opsiria SWOT Analysis, 2017

Table 23: Product Profile – Durasert

Table 24: Durasert SWOT Analysis, 2017

Table 25: Product Profile – EGP-437

Table 26: EGP-437 SWOT Analysis, 2017

Table 27: Product Profile – CLS-TA

Table 28: CLS-TA SWOT Analysis, 2017

Table 29: Product Profile – ADX-102

Table 30: ADX-102 SWOT Analysis, 2017

Table 31: Adalimumab Biosimilars Being Developed in the 7MM/Globally

Table 32: Product Profile – Amjevita

Table 33: Amjevita SWOT Analysis, 2017

Table 34: Product Profile – Imraldi

Table 35: Imraldi SWOT Analysis, 2017

Table 36: Innovative Early Stage Approaches for Non-infectious Uveitis, 2017

Table 37: Drugs in Development for Uveitis, 2017

Table 38: Clinical Benchmark of Key Pipeline Drugs – Anterior Uveitis

Table 39: Clinical Benchmark of Key Pipeline Drugs – Posterior Segment Uveitis

Table 40: Commercial Benchmark of Key Pipeline Drugs – Anterior Uveitis

Table 41: Commercial Benchmark of Key Pipeline Drugs – Posterior Segment Uveitis

Table 42: Key Events Impacting Sales for Uveitis, 2016–2026

Table 43: Uveitis Market – Global Drivers and Barriers, 2016–2026

Table 44: Key Historical and Projected Launch Dates for Uveitis

Table 45: Key Historical and Projected Patent Expiry Dates for Uveitis

Table 46: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for Uveitis in 2016 and 2026

Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care, Pred Forte

Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against Local Therapy, Triesence

Figure 4: Anatomy of the Eye

Figure 5: Hypothetical Pathogenetic Model of Autoimmune Uveitis

Figure 6: Schematic Representation of T-helper Activation In Immune-Mediated Uveitis

Figure 7: Age-Standardized Diagnosed Prevalence of Uveitis, Men, All Ages, 2006–2026

Figure 8: Age-Standardized Diagnosed Prevalence of Uveitis, Women, All Ages, 2006–2026

Figure 9: Case Flow Map for Diagnosed Incident and Prevalent Cases of Uveitis

Figure 10: Sources Used for Diagnosed Incidence

Figure 11: Sources Used for Diagnosed Incident Cases by Anatomical Location of Inflammation

Figure 12: Sources Used for Diagnosed Incident Cases by Course of Disease

Figure 13: Sources Used for Diagnosed Incident Cases by Severity

Figure 14: Sources Used and Not Used for Diagnosed Prevalence

Figure 15: Sources Used for Diagnosed Prevalent Cases by Anatomical Location of Inflammation

Figure 16: 7MM, Age-Specific Diagnosed Prevalent Cases of Uveitis, Both Sexes, N, 2016

Figure 17: 7MM, Sex-Specific Diagnosed Prevalent Cases of Uveitis, All Ages, N, 2016

Figure 18: 7MM, Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation, Both Sexes, All Ages, N, 2016

Figure 19: 7MM, Diagnosed Prevalent Cases of Uveitis by Etiology, Both Sexes, All Ages, N, 2016

Figure 20: Current Treatment of Uveitis

Figure 21: Unmet Need and Opportunity in Non-infectious Uveitis, 2017

Figure 22: Overview of the Development Pipeline in Non-infectious Uveitis

Figure 23: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects Will Be Licensed for Non-infectious Uveitis in the 7MM During the Forecast Period

Figure 24: Competitive Assessment of the Late-Stage Pipeline Drugs for Anterior Segment Uveitis Benchmarked Against the SOC, Pred Forte

Figure 25: Competitive Assessment of the Late-Stage Pipeline Drugs for Posterior Segment Uveitis Benchmarked Against the local therapy, Triesence

Figure 26: Global (7MM) Sales Forecast by Country for Uveitis in 2016 and 2026

Figure 27: Global Sales Forecast by Class for Uveitis in 2016 and 2026

Figure 28: Sales Forecast by Class for Uveitis in the US in 2016 and 2026

Figure 29: Sales Forecast by Class for Uveitis in the 5EU in 2016 and 2026

Figure 30: Sales Forecast by Class for Uveitis in Japan in 2016 and 2026

Frequently asked questions

OpportunityAnalyzer: Uveitis Opportunity Analysis and Forecasts to 2026 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

OpportunityAnalyzer: Uveitis Opportunity Analysis and Forecasts to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at OpportunityAnalyzer: Uveitis Opportunity Analysis and Forecasts to 2026 in real time.

  • Access a live OpportunityAnalyzer: Uveitis Opportunity Analysis and Forecasts to 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.